Marker Therapeutics, Inc.
MRKR
$1.42
-$0.04-2.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -46.19% | -12.99% | 44.55% | 71.52% | 99.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.19% | -12.99% | 44.55% | 71.52% | 99.06% |
| Cost of Revenue | -12.39% | 34.05% | 65.78% | 45.89% | 29.29% |
| Gross Profit | -20.00% | -79.35% | -79.32% | -32.37% | 3.22% |
| SG&A Expenses | -1.34% | -4.93% | -18.52% | -32.69% | -43.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.74% | 22.57% | 36.30% | 14.12% | -1.02% |
| Operating Income | -11.86% | -41.39% | -33.50% | 0.75% | 23.75% |
| Income Before Tax | -14.02% | -47.95% | -41.28% | -4.30% | 23.93% |
| Income Tax Expenses | -130.40% | 1,251.35% | 1,251.35% | 1,251.35% | 1,251.35% |
| Earnings from Continuing Operations | -13.35% | -48.42% | -41.72% | -4.67% | 23.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.35% | -47.45% | -40.86% | -125.79% | -30.28% |
| EBIT | -11.86% | -41.39% | -33.50% | 0.75% | 23.75% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 24.87% | -12.57% | -16.87% | -108.00% | -27.19% |
| Normalized Basic EPS | 27.90% | -9.04% | -13.62% | 7.51% | 25.69% |
| EPS Diluted | 24.95% | -12.28% | -16.56% | -106.83% | -26.92% |
| Normalized Diluted EPS | 27.90% | -9.04% | -13.62% | 7.51% | 25.69% |
| Average Basic Shares Outstanding | 70.32% | 43.12% | 21.46% | 7.64% | 1.94% |
| Average Diluted Shares Outstanding | 70.32% | 43.12% | 21.46% | 7.64% | 1.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |